M+ CRPC and pre-chemotherapy hormonal manipulation: the PREVAIL data
Speakers:
Fred Saad, MD
Objectives
To review the data of the PREVAIL trial
To discuss the added benefit of Xtandi in CRPC chemotherapy naïve patients
To discuss the role of the radiation oncologist, the urologist, and the medical oncologist in the management of these patients.